

Sagent Pharmaceuticals, Inc., a privately-held specialty pharmaceutical company, recently announced the acquisition of Infusive Technologies' proprietary, patented, multi-chamber, sequential dose syringe technology.

Sagent's innovative, dual-chamber syringe enables the sequential administration of two separate intravenous (IV) medications with a single syringe push, thereby replacing two syringes with one. The benefits of this single delivery capability include increasing the speed and ease of drug administration; reducing risk of hospital acquired infection by reducing the number of connections; lowering the risk of drug administration or sequence errors, and quicker delivery of emergency medicines requiring an immediate sequential flush. The unique dual-chamber syringe can accommodate lyophilized, powder or liquid formulations in the front chamber combined with diluents, saline or heparin flush in the rear chamber.

[Click here for the full story.](#)

[Click here to view the syringe animation.](#)

Sagent's innovative, dual-chamber syringe enables the sequential administration of two separate intravenous (IV) medications with a single syringe push, thereby replacing two syringes with one. The benefits of this single delivery capability include increasing the speed and ease of drug administration; reducing risk of hospital acquired infection by reducing the number of connections; lowering the risk of drug administration or sequence errors, and quicker delivery of emergency medicines requiring an immediate sequential flush. The unique dual-chamber syringe can accommodate lyophilized, powder or liquid formulations in the front chamber combined with diluents, saline or heparin flush in the rear chamber.

[Click here for the full story.](#)

[Click here to view the syringe animation.](#)